[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-368126-105":59,"doc-detail-368126-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","al1614311-is-identified-as-a-biomarker-for-bladder-cancer-progression-and-immunotherapy-response","AL161431.1 is Identified as a Biomarker for Bladder Cancer Progression and Immunotherapy Response","","LncRNA AL161431.1 is elevated in bladder cancer tissues relative to normal tissues in TCGA data, and patients with high expression show more advanced clinicopathological stages and shorter survival. AL161431.1 functions as an independent prognostic factor and correlates with immune infiltration, tumor mutation burden, immune checkpoints, and differential sensitivity to immunotherapy. Pathway enrichment links AL161431.1 to immune signaling networks, and qRT-PCR together with CCK-8, transwell, and wound-healing assays confirm its oncogenic effects, supporting its biomarker potential for BLCA prognosis.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/al1614311-is-identified-as-a-biomarker-for-bladder-cancer-progression-and-immunotherapy-response/368126/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/al1614311-is-identified-as-a-biomarker-for-bladder-cancer-progression-and-immunotherapy-response/368126.png","ImageObject",300,407,{"name":92,"@type":93},"Logic","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-24","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What clinical relationship does AL161431.1 show in bladder cancer prognosis?","Question",{"text":112,"@type":113},"High AL161431.1 expression associates with more advanced clinicopathological stages and shorter survival, and AL161431.1 is an independent prognostic factor for bladder cancer.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was the diagnostic and prognostic value of AL161431.1 evaluated?",{"text":117,"@type":113},"TCGA clinical data were analyzed using R packages; survival analyses compared overall survival, disease-specific survival, and progression-free interval between high and low expression groups, and ROC curves assessed diagnostic performance.",{"name":119,"@type":110,"acceptedAnswer":120},"What experimental methods supported the biological role of AL161431.1?",{"text":121,"@type":113},"AL161431.1 oncogenic effects were confirmed using qRT-PCR for expression and functional assays including CCK-8, transwell, and wound healing, alongside enrichment analyses linking it to immune signaling pathways.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},368126,1790219866,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":19,"preview_urls":145},1099513958762,"https://ap-avatar.wpscdn.com/avatar/1000023916a998db790?x-image-process=image/resize,m_fixed,w_180,h_180&k=1784791008015729253","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nAL161431.1 is identified as abiomarker for bladder cancer progression and immunotherapy response  \nSihao Zhang1, Yaxuan Wang1, Zhenwei Han1, Baosai Lu1, Kexin Sun1, Zhihai Teng1, Chenggen Jin1, Fang Li2, Hao Yuan1, Fengran Guo1 & Yanping Zhang1􀀍  \nLncRNA AL161431.1 is currently known as a factor that can promote epithelial-mesenchymal transition. However, its role in the prognosis, immune infiltration and progression of bladder cancer (BLCA)patients is still unclear. The expression of AL161431.1 is elevated in BLCA tissues compared to normal tissues according to theTCGA database. By combining this data with clinical information, patients with high AL161431.1 expression have more advanced clinicopathological stages and shorter survival periods. Furthermore, AL161431.1 was identified as an independent prognostic factor for bladder cancer. We further analyzed the differences in immune infiltration, tumor mutation burden (TMB), immune checkpoints, and sensitivity to immunotherapy between groups with different levels of AL161431.1 expression. Enrichment analysis demonstrated that AL161431.1 is associated with numerous immune signaling pathways. High expression of AL161431.1 in cancer tissues was confirmed by qRT-PCR. CCK8, transwell, and wound healing demonstrated the oncogenic effects of AL161431.1 . In conclusion, AL161431.1 is associated with immune infiltration in bladder cancer and has the potential to become a biomarker for predicting the prognosis of BLCA.  \nKeywords LncRNA AL161431.1, Bladder cancer, Tumor immune microenvironment, Diagnosis, Tumor mutation burden (TMB), Epithelial-mesenchymal transition (EMT)  \nBladder cancer is a urinary system malignancy with high morbidity and mortality. According to reports, bladder cancer stands as the tenth most common cancer globally, with an annual influx of over 430,000 new cases1,2. Despite advancements in clinical management, patients with BLCA are often confronted with tumor recurrence, progression, and metastasis. The 5-year recurrence-free survival rate for non-muscle-invasive BLCA is 23 − 43%, while the 5-year overall survival rate for muscle-invasive BLCA is 36 − 48%2,3. Unfortunately, there is currently a lack of widely recognized prognostic tissue biomarkers for BLCA4, making it difficult for urologists to make precise treatment decisions. Therefore, it is urgent and important to search for new molecular targets to control the invasion and distant metastasis of BLCA.  \nIn recent years, the spotlight has fallen on long non-coding RNAs (lncRNAs), a class of transcripts that have transcended their initial designation as ‘dark matter’ in the genome. With a length exceeding 200 nucleotides and an absence of protein-coding potential, lncRNAs have emerged as key orchestrators in the complex interplay of tumor biology, influencing proliferation, metastasis, cell cycle, and apoptosis5,6. The burgeoning evidence supporting the role of lncRNAs as prognostic biomarkers and therapeutic targets in various cancers, particularly in the urinary tract, has opened new avenues for research and clinical applications7–9. Among the lncRNAs that have captured scientific interest, AL161431.1 stands out as a potential harbinger of prognosis in bladder cancer. Its reported involvement in the pathogenesis of a spectrum of cancers, including head and necksquamous cell carcinoma10, endometrial cancer11, pancreatic cancer12, lung adenocarcinoma13, lung squamous cell carcinoma14, and breast cancer15.  \nThis study aims to elucidate the role of lncRNA AL161431.1 in bladder cancer, leveraging bioinformatics analysis and in vitro experiments to explore its prognostic significance and its intricate relationship with immune cell infiltration, thereby potentially unveiling a new horizon in bladder cancer management.  \n1Department of Urology, The Second Hospital of Hebei Medical University, 215 West Heping Road, Shijiazhuang 050011, ","cbCaikDWd6uUmAsx","https://ap.wps.com/l/cbCaikDWd6uUmAsx","pdf",8869607,12,"English","# Materials and methods\n## Patients\n## Data sources and preprocessing\n## Correction analysis between AL161431.1 expression and BLCA prognosis","[{\"question\":\"What clinical relationship does AL161431.1 show in bladder cancer prognosis?\",\"answer\":\"High AL161431.1 expression associates with more advanced clinicopathological stages and shorter survival, and AL161431.1 is an independent prognostic factor for bladder cancer.\"},{\"question\":\"How was the diagnostic and prognostic value of AL161431.1 evaluated?\",\"answer\":\"TCGA clinical data were analyzed using R packages; survival analyses compared overall survival, disease-specific survival, and progression-free interval between high and low expression groups, and ROC curves assessed diagnostic performance.\"},{\"question\":\"What experimental methods supported the biological role of AL161431.1?\",\"answer\":\"AL161431.1 oncogenic effects were confirmed using qRT-PCR for expression and functional assays including CCK-8, transwell, and wound healing, alongside enrichment analyses linking it to immune signaling pathways.\"}]","AL161431.1 is Identified as a Biomarker for Bladder Cancer Progression and Immunotherapy Response | PDF",1790175114,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b2afc25c829a6a6ffbb8f8abe67f71d0.webp",983,1291,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cfe97639841db7ee548959957d00e00f.webp",982,1290,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/693cae756f78d1b2972597e3c699e85c.webp",981,1289,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/33f342f85235959c0a5726fc2c78bbdf.webp",980,1287]